175 related articles for article (PubMed ID: 2226098)
1. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990.
Smith JP; Solomon TE; Bagheri S; Kramer S
Dig Dis Sci; 1990 Nov; 35(11):1377-84. PubMed ID: 2226098
[TBL] [Abstract][Full Text] [Related]
2. Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat.
Sperti C; Militello C; Rovati L; Behboo R; Khajeturian E; Perasole A; Alaggio R; Pedrazzoli S
J Surg Oncol; 1994 Sep; 57(1):11-6. PubMed ID: 8065144
[TBL] [Abstract][Full Text] [Related]
3. Trophic effects of unsulfated cholecystokinin on mouse pancreas and human pancreatic cancer.
Heald EB; Kramer ST; Smith JP
Pancreas; 1992; 7(5):530-5. PubMed ID: 1381096
[TBL] [Abstract][Full Text] [Related]
4. Effects of pancreastatin (24-49) on growth of normal pancreas and pancreatic cancer.
Smith JP; Kramer S; Bagheri S
Pancreas; 1991 Sep; 6(5):551-7. PubMed ID: 1946312
[TBL] [Abstract][Full Text] [Related]
5. A comparison of secretory actions of VIP, secretin and CCK-PZ in the isolated and perfused kitten pancreas.
Kanno T; Saito A
Endocrinol Jpn; 1980 Dec; 27 Suppl 1():51-7. PubMed ID: 7227320
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of a cholecystokinin antagonist, loxiglumide (CR-1505), on the growth of freshly separated and xenografted human pancreatic cancer.
Morimoto H; Nio Y; Tsubono M; Tseng CC; Kawabata K; Masai Y; Hayashi H; Baba N; Manabe T; Hosokawa Y
J Surg Oncol; 1993 May; 53(1):47-53. PubMed ID: 8386784
[TBL] [Abstract][Full Text] [Related]
7. The effects of graded doses of a cholecystokinin-like peptide with and without secretin on pancreatic growth and synthesis of RNA and polyamines in rats.
Haarstad H; Petersen H
Scand J Gastroenterol; 1989 Oct; 24(8):907-15. PubMed ID: 2480634
[TBL] [Abstract][Full Text] [Related]
8. Interaction of cholecystokinin and vasoactive intestinal polypeptide on function of mouse pancreatic acini in vitro.
Burnham DB; McChesney DJ; Thurston KC; Williams JA
J Physiol; 1984 Apr; 349():475-82. PubMed ID: 6204039
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
10. Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters.
Meijers M; van Garderen-Hoetmer A; Lamers CB; Rovati LC; Jansen JB; Woutersen RA
Carcinogenesis; 1990 Dec; 11(12):2223-6. PubMed ID: 2265473
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice.
Niederau C; Liddle RA; Williams JA; Grendell JH
Gut; 1987; 28 Suppl(Suppl):63-9. PubMed ID: 2446964
[TBL] [Abstract][Full Text] [Related]
12. The influence of cholecystokinin, vasoactive intestinal peptide and secretin on pancreatic and biliary secretion in laying hens.
Duke GE; Larntz K; Hunt H
Comp Biochem Physiol C Comp Pharmacol Toxicol; 1987; 86(1):97-102. PubMed ID: 2881734
[TBL] [Abstract][Full Text] [Related]
13. Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer.
Smith JP; Solomon TE
Gastroenterology; 1988 Dec; 95(6):1541-8. PubMed ID: 2903111
[TBL] [Abstract][Full Text] [Related]
14. Role of cholecystokinin in pancreatic exocrine response to intraluminal amino acids and fat.
Stubbs RS; Stabile BE
Am J Physiol; 1985 Mar; 248(3 Pt 1):G347-52. PubMed ID: 2858160
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of pancreatic growth induced by pancreatico-biliary diversion in the rat. Inhibition by proglumide, benzotript, and ranitidine.
Miazza BM; Turberg Y; Guillaume P; Hahne W; Chayvialle JA; Loizeau E
Scand J Gastroenterol Suppl; 1985; 112():75-83. PubMed ID: 2409583
[TBL] [Abstract][Full Text] [Related]
16. Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.
Smith JP; Cooper TK; McGovern CO; Gilius EL; Zhong Q; Liao J; Molinolo AA; Gutkind JS; Matters GL
Pancreas; 2014 Oct; 43(7):1050-9. PubMed ID: 25058882
[TBL] [Abstract][Full Text] [Related]
17. The trophic effect on the pancreas of long-term continuous intravenous infusion of secretin and a cholecystokinin-like peptide in rats.
Haarstad H; Steffensrud S; Winnberg A; Petersen H
Scand J Gastroenterol; 1986 Jun; 21(5):589-97. PubMed ID: 2428095
[TBL] [Abstract][Full Text] [Related]
18. Potent stimulation of the avian exocrine pancreas by porcine and chicken vasoactive intestinal peptide.
Dimaline R; Dockray GJ
J Physiol; 1979 Sep; 294():153-63. PubMed ID: 512939
[TBL] [Abstract][Full Text] [Related]
19. Cholecystokinin downregulates receptors for vasoactive intestinal peptide and secretin in rat pancreatic acini.
Katsushima S; Adachi H; Honda T; Sato S; Kusui T; Onishi S; Aoki E; Noguchi M; Konishi J
Am J Physiol; 1990 Mar; 258(3 Pt 1):G395-403. PubMed ID: 2156442
[TBL] [Abstract][Full Text] [Related]
20. Combined effect of chronic bombesin and secretin or cholecystokinin on the rat pancreas.
Lhoste E; Aprahamian M; Pousse A; Hoeltzel A; Stock-Damge C
Peptides; 1985; 6 Suppl 3():83-7. PubMed ID: 2421268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
